Pediatric attention-deficit/hyperactivity disorder (ADHD) is a common childhood condition that can continue through adolescence and into adulthood. Despite a number of available—and largely efficacious—pharmacological treatments, opportunity exists for emerging agents that offer improvements in efficacy(including alleviating secondary symptom domains, such as executive functioning) and in safety and tolerability, most notably in terms of the risk for abuse and dependence. The high percentage of patients with inadequate progress in controlling ADHD symptoms, coupled with the need for better maintenance over the long term and other areas requiring considerable advancement, poses a large unmet need and ample commercial opportunity for a new drug to improve pediatric ADHD treatment.

QUESTIONS ANSWERED

  • What are surveyed psychiatrists’ opinions of the relative performance of select therapies, including Vyvanse/Elvanse (Shire) and Metadate CD (UCB)/Quasym LP/Equasym Retard/XL (Shire), on key efficacy, safety/tolerability, and convenience of administration attributes?
  • What are the top areas of unmet need in pediatric ADHD, and which therapies in development, if any, are poised to meet these needs?
  • How much of an improvement would surveyed psychiatrists like to see on the key clinical attributes from emerging therapies versus current therapies?
  • What trade-offs in drug price and performance across key drug attributes are surveyed psychiatrists willing to make?

PRODUCT DESCRIPTION

Unmet Need provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, United Kingdom, France, Germany.

Primary research: Survey of 60 psychiatrists in the United States and 30 psychiatrists in Europe.

Key companies: Eli Lilly, Janssen, Novartis, Shire.

Key drugs: Vyvanse/Elvanse, Concerta, Strattera, Intuniv.

Key metrics included:

  • Stated versus derived analysis of U.S. and European physician prescribing behavior.
  • Conjoint analysis with U.S. and European physicians, includingamarket simulator.
  • Assessment of current drug performance against treatment drivers and goals.
  • Physician perceptions of unmet need in disease/subpopulation covered and related diseases/subpopulations.
  • Analysis of remaining drug development opportunities.

Table of contents

  • Attention-Deficit-Hyperactivity Disorder - Unmet Need - Detailed, Expanded Analysis (US & EU)
    • Introduction
      • Overview
      • Methodology
      • Rationale for Treatment Drivers and Goals Selection
        • Efficacy
        • Safety and Tolerability
        • Convenience of Administration
      • Rationale for Drug Selection
        • Products for Pediatric ADHD
    • Treatment Drivers and Goals
      • Key Findings: Attribute Importance
      • Relative Importance of Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Surveyed Psychiatrists' Prescribing Decisions in Pediatric ADHD
      • Importance of Efficacy Attributes to Prescribing Decisions in Pediatric ADHD: United States
      • Importance of Efficacy Attributes to Prescribing Decisions in Pediatric ADHD: Europe
      • Importance of Safety and Tolerability Attributes to Prescribing Decisions in Pediatric ADHD: United States
      • Importance of Safety and Tolerability Attributes to Prescribing Decisions in Pediatric ADHD: Europe
      • Importance of Convenience of Administration Attributes to Prescribing Decisions in Pediatric ADHD: United States
      • Importance of Convenience of Administration Attributes to Prescribing Decisions in Pediatric ADHD: Europe
      • Key Findings: Stated vs. Derived Importance
      • Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions in Pediatric ADHD: United States
      • Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions in Pediatric ADHD: Europe
    • Product Performance Against Treatment Drivers and Goals
      • Key Findings
      • Overall Performance of Key Therapies for Pediatric ADHD: United States
      • Overall Performance of Key Therapies for Pediatric ADHD: Europe
      • Relative Performance of Key Therapies for Pediatric ADHD Across Select Efficacy Attributes: United States
      • Relative Performance of Key Therapies for Pediatric ADHD Across Select Efficacy Attributes: Europe
      • Relative Performance of Key Therapies for Pediatric ADHD Across Select Safety and Tolerability Attributes: United States
      • Relative Performance of Key Therapies for Pediatric ADHD Across Select Safety and Tolerability Attributes: Europe
      • Relative Performance of Key Therapies for Pediatric ADHD Across Select Convenience of Administration Attributes: United States
      • Relative Performance of Key Therapies for Pediatric ADHD Across Select Convenience of Administration Attributes: Europe
    • Assessment of Unmet Need
      • Key Findings: Unmet Need in Pediatric ADHD
      • Surveyed Psychiatrists' Satisfaction with the Performance of Key Therapies for Pediatric ADHD on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: United States
      • Surveyed Psychiatrists' Satisfaction with the Performance of Key Therapies for Pediatric ADHD on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: Europe
      • Surveyed Psychiatrists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Pediatric ADHD: United States
      • Surveyed Psychiatrists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Pediatric ADHD: Europe
      • Surveyed Psychiatrists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Pediatric ADHD: United States
      • Surveyed Psychiatrists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Pediatric ADHD: Europe
      • Surveyed Psychiatrists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Pediatric ADHD: United States
      • Surveyed Psychiatrists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Pediatric ADHD: Europe
      • Key Findings: Unmet Need in Pediatric ADHD and Related Indications
      • Surveyed Psychiatrists Ascribed Level of Unmet Need in Pediatric ADHD and Related Indications: United States
      • Surveyed Psychiatrists' Ascribed Level of Unmet Need in Pediatric ADHD and Related Indications: Europe
    • Opportunity Analysis
      • Areas of Opportunity in the Pediatric ADHD Market and Emerging Therapy Insights
        • Opportunity: A New Therapy with Improved Efficacy, as Measured by a Greater Reduction on Investigator-Rated ADHD-RS-IV Total Score
        • Opportunity: A New Therapy Offering Better Maintenance in Controlling ADHD Symptoms over the Long Term
    • Target Product Profiles
      • Assessing Drug Development Opportunities
      • Target Product Profile Methodology
        • Attributes and Attribute Levels
      • Attribute Importance and Part-Worth Utilities
        • Pediatric ADHD Target Product Profile: Attribute Importance
        • Reduction from Baseline on Investigator-Rated ADHD-RS-IV Total Score, Placebo-Adjusted
        • Percentage of Patients Failing Treatment over Trial Period, Placebo-Adjusted
        • Percentage of Patients Attaining "Much"/"Very Much" Improved Rating on CGI-I scale
        • Risk of Serious Adverse Events (e.g., cardiovascular, psychiatric events, death)
        • Controlled Substance Restrictions Imposed on Manufacture/Distribution/Prescription
        • Delivery Profile (i.e., dosing formulation and frequency)
        • Price Per Treated Day Relative to Vyvanse/Elvanse
      • Conjoint Analysis-Based Simulations of Market Scenarios
        • Pediatric ADHD Market Simulations: Share of Preference of Target Product Profiles Included in Scenario 1
        • Pediatric ADHD Market Simulations: Likelihood to Prescribe Target Product Profiles Included in Scenario 1
        • Pediatric ADHD Market Simulations: Target Product Profiles Included in Scenario 1
        • Pediatric ADHD Market Simulations: Share of Preference of Target Product Profiles Included in Scenario 2
        • Pediatric ADHD Market Simulations: Likelihood to Prescribe Target Product Profiles Included in Scenario 2
        • Pediatric ADHD Market Simulations: Target Product Profiles Included in Scenario 2
    • Appendix
      • Key Abbreviations
      • Bibliography

Author(s): Audreza Das, P.G. Dip.

Audreza Das is a Senior Analyst in the CNS/Ophthalmology team at Decision Resources Group

She has authored content across indications, including neuropathic pain, age-related macular degeneration, treatment-related depression, painful diabetic neuropathy, and migraine. Ms. Das has previously worked at Novo Nordisk, as a Market Analyst for European markets. Previous experience at a SME, included developing disease competitive landscapes, covering global conferences etc. Ms. Das received her B.E. degree in Biotechnology from Birla Institute of Technology, a deemed university and her P.G. Diploma in Cancer Immunology & Biotechnology from University of Nottingham.